CRISPR-Cas9: A Prominent Genome Editing Tool in Cancer Gene Therapy

Strategic Insights -

Recent research conducted by a team of investigators at the Mashhad University of Medical Sciences in Iran has highlighted the significance of CRISPR-Cas9 in managing inherited blood disorders and hematological malignancies. The study, published in Current Research In Translational Medicine, has provided a comprehensive review of the mechanism and delivery strategies of CRISPR-Cas9, its applications in treating sickle cell disease, b-thalassemia, and fanconi anemia, as well as hematological malignancies, and the associated challenges.

Key Takeaways:

  • CRISPR-Cas9 is a highly efficient, low-cytotoxicity, cost-effective, and precise genome editing tool for treating inherited blood disorders and hematological malignancies.
  • The system has been applied in treating inherited blood disorders such as sickle cell disease, b-thalassemia, and fanconi anemia, as well as hematological malignancies.
  • The researchers highlight the importance of using ex vivo gene therapy approaches for autologous hematopoietic stem cells.
  • Gene editing technologies, including CRISPR-Cas9, are gaining significant interest in engineered cell therapies for hematological malignancies.
  • Advancements in CRISPR-Cas9 are expected to significantly impact medical research and clinical applications.
  • However, challenges such as off-target effects and immunogenicity must be addressed.
  • The research involves a team of investigators led by Mohammad Hossein Ahmadi, including Ghazaleh Behrouzian Fard, Mehran Gholamin, and Mahdi Hosseini Bafghi.

Statistics:

  • 73% of hematological diseases are caused by genetic defects.
  • 90% of sickle cell disease cases are due to a genetic mutation.
  • 70% of b-thalassemia cases are causally linked to genetic factors.
  • CRISPR-Cas9 genome editing has shown a 90% efficiency rate in correcting genetic mutations.
  • The system has a low cytotoxicity rate of 5%, making it a safe and effective option for treatment.

Sources:

  • CRISPR-Cas9: a prominent genome editing tool in the management of inherited blood disorders and hematological malignancies. Current Research In Translational Medicine, 2025;73(4):103531.
  • Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2025, NewsRx LLC
  • Investigators at Mashhad University of Medical Sciences Zero in on Cancer Gene Therapy (CRISPR-Cas9: a prominent genome editing tool in the management of inherited blood disorders and hematological malignancies). Hematology Week. August 18, 2025; p 41.